Guijian Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guijian Liu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Junbo Ge
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases
5 shared publications - Kuan Cheng
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4 shared publications - Qingxing Chen
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4 shared publications - Tao Yu
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4 shared publications - Ye Xu
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4 shared publications - Yunlong Ling
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 19 (1) , 124
Suppression of Calpain Attenuates Coxsackievirus B3-Induced Myocarditis by Regulating RIPK1/RIPK3/MLKL Pathway
- 28 September 2026
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 19 (1) , 124
Open AccessSuppression of Calpain Attenuates Coxsackievirus B3-Induced Myocarditis by Regulating RIPK1/RIPK3/MLKL Pathway
- Open Access
- 25 August 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (9) , 412
Factors Influencing Left Ventricular Thrombus Recurrence After Resolution
Background: Left ventricular thrombus (LVT) is a serious complication associated with cardiomyopathy and impaired left ventricular (LV) systolic function. Patients with a resolved LVT remain at risk for recurrence and subsequent thromboembolism. However, the factors influencing the recurrence of LVT are not yet fully understood. The aim of this study was to identify the risk factors and clinical outcomes related to LVT recurrence and to improve follow-up strategies and treatment options. Methods and results: We retrospectively investigated patients confirmed to have a resolved LVT by transthoracic echocardiography from January 2018 to April 2021 at Zhongshan Hospital Fudan University. All patients received anticoagulant therapy for more than 6 months and underwent at least two follow-up transthoracic echocardiograms. No statistically significant differences were observed in baseline characteristics between the LVT recurrence and non-recurrence groups, including gender, age, diabetes, hyperlipidemia, renal function, previous stroke history, other underlying medical conditions, ejection fraction, or left ventricular diameter. Patients in the recurrence group exhibited a higher prevalence of previous myocardial infarction and percutaneous coronary intervention compared to the non-recurrence group (84.6% vs. 61.1%, p = 0.03; 76.9% vs. 52.8%, p = 0.03). Additionally, patients in the recurrence group tended to have more ventricular aneurysms (50.0% vs. 22.2%, p = 0.008) and larger previous thrombus sizes (27.7 ± 12.6 vs. 21.4 ± 9.1 mm, p = 0.008) compared to those in the non-recurrence group. Multivariate logistic regression analysis indicated that the longitudinal diameter of the LVT was an independent risk factor for LVT recurrence (OR 1.058, 95% CI 1.003–1.115, p = 0.04). ROC curve analysis revealed an area under the curve of 0.647 for the longitudinal diameter of the LVT, with an optimal cut-off value of 23.5 mm, a sensitivity of 62%, and a specificity of 64%. After a follow-up duration of 3.0 ± 2.5 years, the incidence of non-fatal myocardial infarction and major adverse cardiovascular events (MACEs) in the recurrence group was significantly higher than that in the non-recurrence group [non-fatal myocardial infarction: 3 (11.5%) vs. 1 (1.4%), p = 0.02; MACE: 7 (26.9%) vs. 7 (9.7%), p = 0.01]. No statistically significant differences were found in bleeding events, systemic embolism, or all-cause death between the two groups. Conclusions: Our study indicates that a history of myocardial infarction, the presence of ventricular aneurysm, and a larger thrombus diameter are significant factors influencing LVT recurrence. Furthermore, the longitudinal diameter of the thrombus is identified as an independent risk factor for recurrence following resolution. The threshold for LVT diameter requiring extended anticoagulation and the required duration of anticoagulation need to be confirmed in future studies.
- 25 August 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (9) , 412
Open AccessFactors Influencing Left Ventricular Thrombus Recurrence After Resolution
Background: Left ventricular thrombus (LVT) is a serious complication associated with cardiomyopathy and impaired left ventricular (LV) systolic function. Patients with a resolved LVT remain at risk for recurrence and subsequent thromboembolism. However, the factors influencing the recurrence of LVT are not yet fully understood. The aim of this study was to identify the risk factors and clinical outcomes related to LVT recurrence and to improve follow-up strategies and treatment options. Methods and results: We retrospectively investigated patients confirmed to have a resolved LVT by transthoracic echocardiography from January 2018 to April 2021 at Zhongshan Hospital Fudan University. All patients received anticoagulant therapy for more than 6 months and underwent at least two follow-up transthoracic echocardiograms. No statistically significant differences were observed in baseline characteristics between the LVT recurrence and non-recurrence groups, including gender, age, diabetes, hyperlipidemia, renal function, previous stroke history, other underlying medical conditions, ejection fraction, or left ventricular diameter. Patients in the recurrence group exhibited a higher prevalence of previous myocardial infarction and percutaneous coronary intervention compared to the non-recurrence group (84.6% vs. 61.1%, p = 0.03; 76.9% vs. 52.8%, p = 0.03). Additionally, patients in the recurrence group tended to have more ventricular aneurysms (50.0% vs. 22.2%, p = 0.008) and larger previous thrombus sizes (27.7 ± 12.6 vs. 21.4 ± 9.1 mm, p = 0.008) compared to those in the non-recurrence group. Multivariate logistic regression analysis indicated that the longitudinal diameter of the LVT was an independent risk factor for LVT recurrence (OR 1.058, 95% CI 1.003–1.115, p = 0.04). ROC curve analysis revealed an area under the curve of 0.647 for the longitudinal diameter of the LVT, with an optimal cut-off value of 23.5 mm, a sensitivity of 62%, and a specificity of 64%. After a follow-up duration of 3.0 ± 2.5 years, the incidence of non-fatal myocardial infarction and major adverse cardiovascular events (MACEs) in the recurrence group was significantly higher than that in the non-recurrence group [non-fatal myocardial infarction: 3 (11.5%) vs. 1 (1.4%), p = 0.02; MACE: 7 (26.9%) vs. 7 (9.7%), p = 0.01]. No statistically significant differences were found in bleeding events, systemic embolism, or all-cause death between the two groups. Conclusions: Our study indicates that a history of myocardial infarction, the presence of ventricular aneurysm, and a larger thrombus diameter are significant factors influencing LVT recurrence. Furthermore, the longitudinal diameter of the thrombus is identified as an independent risk factor for recurrence following resolution. The threshold for LVT diameter requiring extended anticoagulation and the required duration of anticoagulation need to be confirmed in future studies.
- Open Access
- 11 August 2026
- Published by MDPI AG in Preprints.org
Factors Influencing Left Ventricular Thrombus Recurrence After Resolution
Background: Left ventricular thrombus (LVT) is a serious complication associated with cardiomyopathy and impaired left ventricular (LV) systolic function. Patients with LVT resolution remain at risk for recurrence and subsequent thromboembolism. However, the factors influencing the recurrence of LVT are not yet fully understood. This study aimed to identify the risk factors and clinical outcomes related to LVT recurrence and to improve follow-up strategies and treatment options. Methods and results: We retrospectively investigated patients diagnosed with LVT on transthoracic echocardiography from January 2018 to April 2021 in Zhongshan Hospital Fudan University. All patients received anticoagulant therapy for more than 6 months and underwent at least two follow-up transthoracic echocardiograms. No statistically significant differences were observed in baseline characteristics between the LVT recurrence and non-recurrence group, regarding gender, age, diabetes, hyperlipidemia, renal function, previous stroke history, other underlying medical conditions, ejection fraction, or left ventricular diameter. Patients in the recurrence group exhibited a higher prevalence of previous myocardial infarction and percutaneous coronary intervention compared to the non-recurrence group (84.6% vs 61.1%, p = 0.03; 76.9% vs 52.8%, p = 0.03). Additionally, patients in the recurrence group tended to have more ventricular aneurysms (50.0% vs 22.2%, p = 0.008) and larger previous thrombus sizes (27.7 ± 12.6 vs 21.4 ± 9.1 mm, p = 0.008) compared to those in the non-recurrence group. Multivariate logistic regression analysis indicated that the longitudinal diameter of the LVT was an independent risk factor for LVT recurrence (OR 1.058, 95% CI 1.003-1.115, p = 0.04). ROC curve analysis revealed an area under the curve of 0.647 for the longitudinal diameter of LVT, with an optimal cut-off value of 23.5mm, a sensitivity of 62%, and a specificity of 64%. After a follow-up of 3.0 ± 2.5 years, the incidence of non-fatal myocardial infarction and major adverse cardiovascular events (MACE) in the recurrence group was significantly higher than in the non-recurrence group [non-fatal myocardial infarction: 3 (11.5%) vs 1 (1.4%), p = 0.02; MACE: 7 (26.9%) vs 7 (9.7%), p = 0.01]. No statistically significant differences were found in bleeding events, systemic embolism, or all-cause death between the two groups. Conclusions: Our study indicates that a history of myocardial infarction, the presence of ventricular aneurysm, and larger thrombus diameter are significant factors influencing LVT recurrence. Furthermore, the longitudinal diameter of the thrombus is identified as an independent risk factor for recurrence following resolution. We recommend patients with a LVT diameter greater than 23.5 mm consider extending their anticoagulant therapy to mitigate the risk of recurrence.
- 11 August 2026
- Published by MDPI AG in Preprints.org
Open AccessFactors Influencing Left Ventricular Thrombus Recurrence After Resolution
Background: Left ventricular thrombus (LVT) is a serious complication associated with cardiomyopathy and impaired left ventricular (LV) systolic function. Patients with LVT resolution remain at risk for recurrence and subsequent thromboembolism. However, the factors influencing the recurrence of LVT are not yet fully understood. This study aimed to identify the risk factors and clinical outcomes related to LVT recurrence and to improve follow-up strategies and treatment options. Methods and results: We retrospectively investigated patients diagnosed with LVT on transthoracic echocardiography from January 2018 to April 2021 in Zhongshan Hospital Fudan University. All patients received anticoagulant therapy for more than 6 months and underwent at least two follow-up transthoracic echocardiograms. No statistically significant differences were observed in baseline characteristics between the LVT recurrence and non-recurrence group, regarding gender, age, diabetes, hyperlipidemia, renal function, previous stroke history, other underlying medical conditions, ejection fraction, or left ventricular diameter. Patients in the recurrence group exhibited a higher prevalence of previous myocardial infarction and percutaneous coronary intervention compared to the non-recurrence group (84.6% vs 61.1%, p = 0.03; 76.9% vs 52.8%, p = 0.03). Additionally, patients in the recurrence group tended to have more ventricular aneurysms (50.0% vs 22.2%, p = 0.008) and larger previous thrombus sizes (27.7 ± 12.6 vs 21.4 ± 9.1 mm, p = 0.008) compared to those in the non-recurrence group. Multivariate logistic regression analysis indicated that the longitudinal diameter of the LVT was an independent risk factor for LVT recurrence (OR 1.058, 95% CI 1.003-1.115, p = 0.04). ROC curve analysis revealed an area under the curve of 0.647 for the longitudinal diameter of LVT, with an optimal cut-off value of 23.5mm, a sensitivity of 62%, and a specificity of 64%. After a follow-up of 3.0 ± 2.5 years, the incidence of non-fatal myocardial infarction and major adverse cardiovascular events (MACE) in the recurrence group was significantly higher than in the non-recurrence group [non-fatal myocardial infarction: 3 (11.5%) vs 1 (1.4%), p = 0.02; MACE: 7 (26.9%) vs 7 (9.7%), p = 0.01]. No statistically significant differences were found in bleeding events, systemic embolism, or all-cause death between the two groups. Conclusions: Our study indicates that a history of myocardial infarction, the presence of ventricular aneurysm, and larger thrombus diameter are significant factors influencing LVT recurrence. Furthermore, the longitudinal diameter of the thrombus is identified as an independent risk factor for recurrence following resolution. We recommend patients with a LVT diameter greater than 23.5 mm consider extending their anticoagulant therapy to mitigate the risk of recurrence.
- Open Access
- 16 June 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 274
Impact of Anterior Mitral Leaflet Length on the Efficacy of Intracardiac Echocardiography-Guided Endocardial Septal Ablation for HOCM
Background: Intracardiac echocardiography (ICE)-guided percutaneous endocardial septal ablation (PESA) is a promising alternative strategy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). However, the extent of left ventricular outflow tract gradient (LVOTG) reduction after PESA varies considerably among patients, and reliable echocardiographic predictors of procedural efficacy remain unclear. We aimed to identify echocardiographic predictors of procedural efficacy and to describe our ablation strategy. Methods: We retrospectively analyzed 30 consecutive symptomatic HOCM patients who underwent ICE-guided PESA. The primary endpoint was the absolute change in resting LVOTG from baseline to the 1-year follow-up; a key secondary endpoint was significant gradient reduction, defined as a ≥50% decrease in resting LVOTG. Associations between LVOTG reduction and baseline echocardiographic parameters, particularly anterior mitral leaflet length (AMLL) and interventricular septal thickness (IVST), were evaluated. Results: At 1 year, the mean resting LVOTG decreased from 86.03 ± 24.30 mmHg to 41.43 ± 18.49 mmHg (p < 0.001). For the key secondary endpoint (≥50% resting LVOTG reduction), AMLL was the only variable associated with the outcome in the prespecified multivariable logistic model (OR per 1 mm increase: 0.429; p = 0.006), with consistent findings in a Firth penalized logistic regression sensitivity analysis. ROC analysis identified an exploratory AMLL cutoff of approximately 29 mm (AUC 0.920; sensitivity 90%; specificity 80%). In the continuous-outcome analysis, each 1 mm increase in AMLL corresponded to approximately 4.3 mmHg less LVOTG reduction (β = −4.32; p < 0.001). Thinner IVST was not significantly associated with greater procedural efficacy (p = 0.052), suggesting a potential thickness-dependent limit that warrants further investigation. Conclusions: ICE-guided PESA effectively reduces LVOT obstruction in HOCM. Shorter AMLL predicted greater LVOT gradient reduction in this exploratory cohort, and a Youden-derived AMLL cutoff of approximately 29 mm may help identify patients who are more likely to achieve substantial gradient reduction.
- 16 June 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 274
Open AccessImpact of Anterior Mitral Leaflet Length on the Efficacy of Intracardiac Echocardiography-Guided Endocardial Septal Ablation for HOCM
Background: Intracardiac echocardiography (ICE)-guided percutaneous endocardial septal ablation (PESA) is a promising alternative strategy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). However, the extent of left ventricular outflow tract gradient (LVOTG) reduction after PESA varies considerably among patients, and reliable echocardiographic predictors of procedural efficacy remain unclear. We aimed to identify echocardiographic predictors of procedural efficacy and to describe our ablation strategy. Methods: We retrospectively analyzed 30 consecutive symptomatic HOCM patients who underwent ICE-guided PESA. The primary endpoint was the absolute change in resting LVOTG from baseline to the 1-year follow-up; a key secondary endpoint was significant gradient reduction, defined as a ≥50% decrease in resting LVOTG. Associations between LVOTG reduction and baseline echocardiographic parameters, particularly anterior mitral leaflet length (AMLL) and interventricular septal thickness (IVST), were evaluated. Results: At 1 year, the mean resting LVOTG decreased from 86.03 ± 24.30 mmHg to 41.43 ± 18.49 mmHg (p < 0.001). For the key secondary endpoint (≥50% resting LVOTG reduction), AMLL was the only variable associated with the outcome in the prespecified multivariable logistic model (OR per 1 mm increase: 0.429; p = 0.006), with consistent findings in a Firth penalized logistic regression sensitivity analysis. ROC analysis identified an exploratory AMLL cutoff of approximately 29 mm (AUC 0.920; sensitivity 90%; specificity 80%). In the continuous-outcome analysis, each 1 mm increase in AMLL corresponded to approximately 4.3 mmHg less LVOTG reduction (β = −4.32; p < 0.001). Thinner IVST was not significantly associated with greater procedural efficacy (p = 0.052), suggesting a potential thickness-dependent limit that warrants further investigation. Conclusions: ICE-guided PESA effectively reduces LVOT obstruction in HOCM. Shorter AMLL predicted greater LVOT gradient reduction in this exploratory cohort, and a Youden-derived AMLL cutoff of approximately 29 mm may help identify patients who are more likely to achieve substantial gradient reduction.
- Open Access
- 4 October 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (10) , 308
Effect of Pulmonary Vein Isolation with Left Atrial Wall Isolation Plus Selective CFAE Ablation in Patients with Persistent Atrial Fibrillation
Background: Pulmonary vein isolation (PVI) is a foundational treatment for persistent atrial fibrillation (PeAF), but the effectiveness of adding posterior wall isolation (PWI) and selective complex fractionated atrial electrogram (CFAE) ablation in the roof and anterior wall remains debated. The potential of these additional ablation techniques to improve long-term outcomes for PeAF patients is still uncertain. Methods: This retrospective study included 151 PeAF patients who underwent first-time catheter ablation at our center. The choice of ablation strategy was based on the operator’s clinical judgment, taking into account the patient’s specific condition and anatomical features. Patients were divided into two groups: the PVI group, which received PVI alone, and the modified PWI (MPWI) group, which received PVI along with additional PWI and selective CFAEs ablation in the roof and anterior wall. The primary endpoint was the absence of atrial arrhythmia lasting more than 30 s, without antiarrhythmic drugs, at 12 months. Results: At the 12-month follow-up, 77.3% of the patients in the MPWI group and 52.1% of the patients in the PVI group remained in sinus rhythm without an atrial arrhythmia recurrence (p = 0.001). The BIC-based Cox regression analysis identified the ablation strategy and atrial fibrillation (AF) duration as independent predictors of recurrence across the cohort. It was found that MPWI significantly reduced the risk of recurrence, while a longer AF duration increased it. In the MPWI group, AF duration, left ventricular internal diameter in systole (LVIDs), and moderate or greater tricuspid regurgitation were independent predictors of recurrence. In the PVI group, only the left atrial low voltage area (LVA) index was a significant predictor. Conclusion: The addition of PWI and selective CFAE ablation to PVI significantly improves 12-month arrhythmia-free survival compared to PVI alone, demonstrating the superiority of this combined approach in improving long-term outcomes for patients with persistent AF.
- 4 October 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (10) , 308
Open AccessEffect of Pulmonary Vein Isolation with Left Atrial Wall Isolation Plus Selective CFAE Ablation in Patients with Persistent Atrial Fibrillation
Background: Pulmonary vein isolation (PVI) is a foundational treatment for persistent atrial fibrillation (PeAF), but the effectiveness of adding posterior wall isolation (PWI) and selective complex fractionated atrial electrogram (CFAE) ablation in the roof and anterior wall remains debated. The potential of these additional ablation techniques to improve long-term outcomes for PeAF patients is still uncertain. Methods: This retrospective study included 151 PeAF patients who underwent first-time catheter ablation at our center. The choice of ablation strategy was based on the operator’s clinical judgment, taking into account the patient’s specific condition and anatomical features. Patients were divided into two groups: the PVI group, which received PVI alone, and the modified PWI (MPWI) group, which received PVI along with additional PWI and selective CFAEs ablation in the roof and anterior wall. The primary endpoint was the absence of atrial arrhythmia lasting more than 30 s, without antiarrhythmic drugs, at 12 months. Results: At the 12-month follow-up, 77.3% of the patients in the MPWI group and 52.1% of the patients in the PVI group remained in sinus rhythm without an atrial arrhythmia recurrence (p = 0.001). The BIC-based Cox regression analysis identified the ablation strategy and atrial fibrillation (AF) duration as independent predictors of recurrence across the cohort. It was found that MPWI significantly reduced the risk of recurrence, while a longer AF duration increased it. In the MPWI group, AF duration, left ventricular internal diameter in systole (LVIDs), and moderate or greater tricuspid regurgitation were independent predictors of recurrence. In the PVI group, only the left atrial low voltage area (LVA) index was a significant predictor. Conclusion: The addition of PWI and selective CFAE ablation to PVI significantly improves 12-month arrhythmia-free survival compared to PVI alone, demonstrating the superiority of this combined approach in improving long-term outcomes for patients with persistent AF.
- Open Access
- 7 September 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8
Six-Year Follow-Up Outcomes of Catheter Ablation of Para-Hisian Accessory Pathways
Background: Ablation of para-hisian accessory pathways (APs) remains challenging due to anatomic characteristics, and a few studies have focused on the causes for recurrence of radiofrequency ablation of para-hisian APs.Objective: This retrospective single center study aimed to explore the risk factors for recurrence of para-hisian APs.Methods: One hundred thirteen patients who had para-hisian AP with an acute success were enrolled in the study. In the 6-year follow-up, 15 cases had a recurrent para-hisian AP. Therefore, 98 patients were classified into the success group, while 15 patients were classified into the recurrence group. Demographic and ablation characteristics were analyzed.Results: Gender difference was similar in two groups. The median age was 36.2 years old and was younger in the recurrence group. Maximum ablation power was significantly higher in the success group (29 ± 7.5 vs. 22.9 ± 7.8, p < 0.01). Ablation time of final target sites was found to be markedly higher in the success group (123.4 ± 53.1 vs. 86.7 ± 58.3, p < 0.05). Ablation time p < 0.01). Occurrence of junctional rhythm was significantly higher in the recurrence group (25.5% vs. 53.3%, p < 0.05). No severe conduction block, no pacemaker implantation, and no stroke were reported. Junctional rhythm during ablation (OR = 3.833, 95% CI 1.083–13.572, p = 0.037) and ablation time p = 0.014) were independent risk factors for the recurrence of para-hisian AP.Conclusions: With careful and accurate mapping, it is relatively safe to ablate para-hisian AP. If possible, proper extension of ablation time could reduce the recurrence rate of para-hisian APs.
- 7 September 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8
Open AccessSix-Year Follow-Up Outcomes of Catheter Ablation of Para-Hisian Accessory Pathways
Background: Ablation of para-hisian accessory pathways (APs) remains challenging due to anatomic characteristics, and a few studies have focused on the causes for recurrence of radiofrequency ablation of para-hisian APs.Objective: This retrospective single center study aimed to explore the risk factors for recurrence of para-hisian APs.Methods: One hundred thirteen patients who had para-hisian AP with an acute success were enrolled in the study. In the 6-year follow-up, 15 cases had a recurrent para-hisian AP. Therefore, 98 patients were classified into the success group, while 15 patients were classified into the recurrence group. Demographic and ablation characteristics were analyzed.Results: Gender difference was similar in two groups. The median age was 36.2 years old and was younger in the recurrence group. Maximum ablation power was significantly higher in the success group (29 ± 7.5 vs. 22.9 ± 7.8, p < 0.01). Ablation time of final target sites was found to be markedly higher in the success group (123.4 ± 53.1 vs. 86.7 ± 58.3, p < 0.05). Ablation time p < 0.01). Occurrence of junctional rhythm was significantly higher in the recurrence group (25.5% vs. 53.3%, p < 0.05). No severe conduction block, no pacemaker implantation, and no stroke were reported. Junctional rhythm during ablation (OR = 3.833, 95% CI 1.083–13.572, p = 0.037) and ablation time p = 0.014) were independent risk factors for the recurrence of para-hisian AP.Conclusions: With careful and accurate mapping, it is relatively safe to ablate para-hisian AP. If possible, proper extension of ablation time could reduce the recurrence rate of para-hisian APs.